Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Nektar Therapeutics patents


Recent patent applications related to Nektar Therapeutics. Nektar Therapeutics is listed as an Agent/Assignee. Note: Nektar Therapeutics may have other listings under different names/spellings. We're not affiliated with Nektar Therapeutics, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "N" | Nektar Therapeutics-related inventors


Oligomer-containing benzamide-based compounds

The invention relates to (among other things) oligomer-containing benzamide-based compound compounds. A compound of the invention exhibits one or more advantages over corresponding compounds lacking the oligomer.. ... Nektar Therapeutics

Polymer-semaxanib moiety conjugates

The invention relates to (among other things) polymer-semaxanib moiety conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over the semaxanib moiety in unconjugated form.. ... Nektar Therapeutics

N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides

The invention relates to (among other things) n-optionally substituted aryl-2-oligomer-3-alkoxypropionamides and compositions comprising the same. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.. ... Nektar Therapeutics

Morphinan derivatives for the treatment of neuropathic pain

The present invention relates to compounds and their use as ligands for mu opioid receptors. Also included are methods for preparing the compounds and pharmaceutical compositions containing the compounds. ... Nektar Therapeutics

Method for predicting and evaluating responsiveness to cancer treatment with dna-damaging chemotherapeutic agents

Provided herein are methods directed to the prediction and early assessment of the efficacy of cancer treatment regimens, in particular in patients undergoing therapy with a dna-damaging chemotherapeutic agent, by determining expression levels of certain proteins found to be useful as biomarkers in circulating tumor cells obtained from the patient both prior to and post-treatment.. . ... Nektar Therapeutics

Conjugates of an il-2 moiety and a polymer

Conjugates of an interleukin-2 (“il-2”) moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the non-peptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. ... Nektar Therapeutics

Method involving 1-benzotriazolyl carbonate esters of poly(ethylene glycol)

The invention provides for preparing a polymer-active agent conjugate, the method comprising the steps of reacting an amino acid derivative with a biologically active agent under conditions to form a polymer-active agent conjugate.. . ... Nektar Therapeutics

N-maleimidyl polymer derivatives

The invention is directed to multi-functional n-maleimidyl polymer derivatives comprising a water soluble and non-peptidic polymer backbone having a terminal carbon, such as a poly(alkylene glycol), the terminal carbon of the polymer backbone being directly bonded to the nitrogen atom of a n-maleimidyl moiety without a linking group therebetween. The invention also provides two methods of preparing such linkerless n-maleimidyl polymer derivatives.. ... Nektar Therapeutics

Polymer-sunitinib conjugates

The invention relates to (among other things) polymer-sunitinib conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over sunitinib in unconjugated form.. ... Nektar Therapeutics

Multi-arm polymer prodrugs

. . Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. ... Nektar Therapeutics

N-methyl-n-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the kappa opioid receptor

. . Compounds and pharmaceutically acceptable salts and solvates thereof are described. The compounds relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology and organic chemistry.. ... Nektar Therapeutics

Oligomer-beta blocker conjugates

The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a different biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.. ... Nektar Therapeutics

Composition comprising a polymeric reagent

The present invention provides conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates. The conjugates as well as the polymeric reagents used to form the conjugates include at least one of each the following: an aromatic moiety comprising an ionizable hydrogen atom, a spacer moiety, and a water-soluble polymer. ... Nektar Therapeutics

Compositions of particulate coformulation

Embodiments of the invention provide a composition of a particulate coformulation which includes particles containing an active substance and an additive, wherein each particle contains a relative additive concentration increasing radially outwards from a particle center to a particle surface along a finite gradient. In one example, the particle surface is an additive-rich surface without a distinct physical boundary between the particle center and the particle surface. ... Nektar Therapeutics

10/05/17 / #20170283552

Methods for preparing polymeric reagents and compositions of polymeric reagents

Methods for preparing active carbonate esters of water-soluble polymers are provided. Also provided are other methods related to the active carbonate esters of water-soluble polymers, as well as corresponding compositions.. ... Nektar Therapeutics

09/28/17 / #20170273920

Particulate materials

The present invention relates to active substances in particulate form, to methods for preparing them and to their uses. The present invention provides particulate powders, such as might be of use for delivery using a dry powder inhaler (dpi) or similar delivery device, having properties which may be beneficial to the dpi delivery process.. ... Nektar Therapeutics

09/07/17 / #20170253565

Opioid agonists and uses thereof

Provided are compounds, including those of formula i; and pharmaceutically acceptable salts and solvates thereof. The compounds described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.. ... Nektar Therapeutics

09/07/17 / #20170252523

Sealed nebulizer liquid reservoir systems and methods

Methods, systems, and devices are described for sealing a nebulizer's liquid reservoir. A nebulizer liquid reservoir may be provided that is in fluid communication with an aerosol generator. ... Nektar Therapeutics

08/17/17 / #20170232014

Oligomer-foscarnet conjugates

The invention relates to (among other things) oligomer-foscarnet conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated foscarnet compounds.. ... Nektar Therapeutics

08/10/17 / #20170226119

Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof

Solid forms of certain opioid agonists are provided herein. Methods of preparing the solid forms, methods of using the solid forms, and pharmaceutical compositions comprising the solid forms are also provided herein.. ... Nektar Therapeutics

07/13/17 / #20170196975

Conjugates of an anti-tnf-alpha antibody

Conjugates of an anti-tnf antibody and one or more nonpeptidic water-soluble polymers are provided. Typically, the nonpeptidic water-soluble polymer is poly(ethylene glycol) or a derivative thereof. ... Nektar Therapeutics

07/06/17 / #20170189369

Multi-arm polymeric alkanoate conjugates

Among other aspects, provided herein are multi-armed polymer conjugates comprising an alkanoate-linker, compositions comprising such conjugates, and related methods of making and administering the same. Methods of treatment employing such conjugates and related uses are also provided. ... Nektar Therapeutics

06/22/17 / #20170173006

Particulate materials

Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing such particles or formulations. In one embodiment, a composition of an aerosol formulation is provided and contains a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 μm suspended in a hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 5% w/v. ... Nektar Therapeutics

06/15/17 / #20170165372

N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides

The invention relates to (among other things) n-optionally substituted aryl-2-oligomer-3-alkoxypropionamides and compositions comprising the same. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.. ... Nektar Therapeutics

05/11/17 / #20170128539

Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an anti-pd-1 antibody

The invention relates to (among other things) method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) an il-2rβ-activating amount of a long acting, il-2rβ-selective agonist; and (b) a ctla-4 pathway-inhibiting amount of an anti-ctla-4 antibody or a pd-1 pathway-inhibiting amount of an anti-pd-1 antibody.. . ... Nektar Therapeutics

05/04/17 / #20170121459

Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method

Provided herein are polymeric α-hydroxy aldehyde or α-hydroxy ketone reagents which can be conjugated to amine-containing compounds to form stable conjugates in a single-step reaction. In selected embodiments, the polymeric reagent itself incorporates an internal proton-abstracting (basic) functional group, to promote more efficient reaction. ... Nektar Therapeutics

04/27/17 / #20170112826

Oligomer-opioid agonist conjugates

The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.. ... Nektar Therapeutics

04/06/17 / #20170095565

Chemically modified small molecules

Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.. . ... Nektar Therapeutics

03/30/17 / #20170088668

N-maleimidyl polymer derivatives

The invention is directed to multi-functional n-maleimidyl polymer derivatives comprising a water soluble and non-peptidic polymer backbone having a terminal carbon, such as a poly(alkylene glycol), the terminal carbon of the polymer backbone being directly bonded to the nitrogen atom of a n-maleimidyl moiety without a linking group therebetween. The invention also provides two methods of preparing such linkerless n-maleimidyl polymer derivatives.. ... Nektar Therapeutics

03/23/17 / #20170079975

Compositions, dosage forms, and co-administration of an opioid agonist compound and an analgesic compound

The present invention relates generally to the co-administration of an opioid agonist compound and an analgesic compound. In addition, the invention relates to, among other things, dosage forms for co-administration of an opioid agonist compound and an analgesic compound, methods for administering an opioid agonist compound and an analgesic compound, compositions comprising an opioid agonist compound and an analgesic compound, dosage forms comprising an opioid agonist compound and an analgesic compound, and so on.. ... Nektar Therapeutics

03/16/17 / #20170073468

Method for preparing functionalized polymers from polymer alcohols

The present invention provides, among other things, compounds that include a water-soluble and non-peptidic polymer as well as a maleimidyl group. The compounds are useful as, among other things, polymeric reagents.. ... Nektar Therapeutics

03/16/17 / #20170072160

Systems and methods for driving nebulizers

In various arrangements, a nebulizer element of a nebulizer may be energized with a drive signal. A phase offset of the drive signal may be measured. ... Nektar Therapeutics

03/09/17 / #20170066782

Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine

The instant disclosure relates to (among other things) compounds that are derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine. The compounds provided possess unique effects and differences over other phenyltriazines known in the art.. ... Nektar Therapeutics

03/02/17 / #20170056514

Multi-arm polymer prodrugs

Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. ... Nektar Therapeutics

02/09/17 / #20170035898

Conjugates of an il-15 moiety and a polymer

Conjugates of an il-15 moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the nonpeptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. ... Nektar Therapeutics

02/09/17 / #20170035896

Polymer factor ix moiety conjugates

Conjugates of a factor ix moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. ... Nektar Therapeutics

02/02/17 / #20170028077

Protease inhibitors having enhanced features

Provided herein (among other things) are protease inhibitor compounds having enhanced features, along with methods for administering such compounds. For example, the subject compounds can be administered without concomitant administration of a cyp3a4 inhibitor, have increased therapeutic index and/or increased potency, and are low-resistance inducing in nature.. ... Nektar Therapeutics

01/26/17 / #20170022167

Opioid agonists and uses thereof

Provided are compounds, including those of formula i; and pharmaceutically acceptable salts and solvates thereof. The compounds described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.. ... Nektar Therapeutics








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Nektar Therapeutics in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Nektar Therapeutics with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###